IQVIA’s (IQV) Equal Weight Rating Reiterated at Barclays

Barclays reaffirmed their equal weight rating on shares of IQVIA (NYSE:IQV) in a research report released on Thursday, MarketBeat reports. They currently have a $170.00 price target on the medical research company’s stock, down from their prior price target of $235.00.

A number of other brokerages also recently weighed in on IQV. Citigroup lowered their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. JPMorgan Chase & Co. dropped their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, Bank of America reduced their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.50.

IQVIA Stock Performance

Shares of IQV opened at $145.40 on Thursday. IQVIA has a 12 month low of $135.97 and a 12 month high of $252.88. The business’s fifty day simple moving average is $182.32 and its two-hundred day simple moving average is $199.64. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market cap of $25.64 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently made changes to their positions in IQV. Vanguard Group Inc. lifted its holdings in IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after purchasing an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock valued at $841,461,000 after buying an additional 712,958 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of IQVIA by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock worth $818,315,000 after buying an additional 77,981 shares in the last quarter. Invesco Ltd. boosted its position in shares of IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock worth $509,012,000 after acquiring an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock valued at $481,380,000 after acquiring an additional 59,426 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.